NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis $0.37 +0.03 (+10.05%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.36 -0.01 (-3.77%) As of 04/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProPhase Labs Stock (NASDAQ:PRPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProPhase Labs alerts:Sign Up Key Stats Today's Range$0.33▼$0.3750-Day Range$0.24▼$0.5952-Week Range$0.22▼$5.62Volume258,300 shsAverage Volume2.64 million shsMarket Capitalization$15.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More… ProPhase Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScorePRPH MarketRank™: ProPhase Labs scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ProPhase Labs. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ProPhase Labs' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.29% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProPhase Labs has recently increased by 49.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.29% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProPhase Labs has recently increased by 49.99%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentProPhase Labs has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProPhase Labs this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PRPH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.45% of the stock of ProPhase Labs is held by institutions.Read more about ProPhase Labs' insider trading history. Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPH Stock News HeadlinesProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 50.0% in MarchApril 18, 2025 | americanbankingnews.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 26, 2025 | American Alternative (Ad)ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024March 31, 2025 | globenewswire.comProPhase Labs FY 2024 Earnings PreviewMarch 28, 2025 | msn.comSee More Headlines PRPH Stock Analysis - Frequently Asked Questions How have PRPH shares performed this year? ProPhase Labs' stock was trading at $0.7571 on January 1st, 2025. Since then, PRPH shares have decreased by 51.3% and is now trading at $0.3689. View the best growth stocks for 2025 here. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) announced its earnings results on Thursday, May, 9th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.21. The business earned $3.63 million during the quarter, compared to analyst estimates of $9.86 million. ProPhase Labs had a negative trailing twelve-month return on equity of 62.92% and a negative net margin of 217.64%. Read the conference call transcript. Who are ProPhase Labs' major shareholders? Top institutional investors of ProPhase Labs include Chapin Davis Inc. (0.19%). View institutional ownership trends. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET). Company Calendar Last Earnings5/09/2024Today4/26/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRPH CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees130Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,780,000.00 Net Margins-217.64% Pretax Margin-298.21% Return on Equity-62.92% Return on Assets-30.22% Debt Debt-to-Equity Ratio0.48 Current Ratio1.47 Quick Ratio1.33 Sales & Book Value Annual Sales$6.77 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book0.13Miscellaneous Outstanding Shares41,879,000Free Float18,932,000Market Cap$15.45 million OptionableOptionable Beta-0.56 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PRPH) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.